Newsroom

Press Releases

ASCO 2025 Highlights: Menin Inhibitor for Acute Myeloid Leukemia; Organ Transplant and Checkpoint Inhibitors

BUFFALO, N.Y. — Faculty from Roswell Park Comprehensive Cancer Center are among the international experts invited to share their research findings at the American Society of Clinical Oncology (ASCO) annual meeting May 30-June 3 at McCormick Place in Chicago.

Friday, May 23, 2025 - 10:00 am

News

Duration of Overweight/Obesity During Treatment Linked to Worse Outcomes in Pediatric Leukemia Patients

New research on children diagnosed with acute lymphoblastic leukemia shows that the longer a patient’s BMI falls within the overweight/obese category during treatment, the greater the risk of relapse and the lower the chance of survival.

Wednesday, May 14, 2025 - 11:00 am

A vial of the SurVaxM vaccine in the Fenstermaker and Ciesielski lab

News

Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM

Roswell Park announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data. Four studies that incorporate SurVaxM are currently underway at Roswell Park and other centers nationally.

Thursday, May 8, 2025 - 01:00 pm

More Press Releases